Apontis Pharma AG Stock
Price
Target price
€8.38
€8.38
-0.240%
-
-0.240%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Apontis Pharma
sharewise wants to provide you with the best news and tools for Apontis Pharma, so we directly link to the best financial data sources.
Financials
News
EQS-News: APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
EQS-News: APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
EQS-News: APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
EQS-News: APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
EQS-News: APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQS-News: APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQS-News: APONTIS PHARMA expects profitable growth again in 2024
EQS-News: APONTIS PHARMA expects profitable growth again in 2024
EQS-News: APONTIS PHARMA successfully completes performance and efficiency improvement program
EQS-News: APONTIS PHARMA successfully completes performance and efficiency improvement program